ArticleBMJ open respiratory research2025
Rheumatoid arthritis and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide longitudinal cohort study.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious literature suggested that rheumatoid arthritis (RA) might be a risk factor for nontuberculous mycobacteria pulmonary disease (NTM-PD). However, longitudinal studies did not comprehensively consider potential confounders such as body mass index and smoking status. In addition, the impact of RA seropositivity has not been well elucidated. In this study, we aimed to evaluate the risk of incident NTM-PD in subjects with RA versus age-matched and sex-matched controls, while focusing on the impact of RA serologic status on this association.
methodsFrom the Korean National Health Insurance Service data from 2010 to 2017, we identified 60 315 participants aged ≥20 years with RA and 301 575 without RA who were age-matched and sex-matched 1:5. The participants were followed up from 1 year after RA diagnosis (or the corresponding index date for matched controls) to the date of NTM-PD diagnosis, censored date or 31 December 2019, whichever occurred first.
resultsDuring a median 4.5 (IQR, 2.6-6.4) year follow-up, NTM-PD occurred in 0.23% and 0.06% of the RA and matched cohort (incidence: 0.54 and 0.14 per 1000 person-years), respectively. Compared with controls, participants with RA had a 3.11-fold (95% CI 2.50 to 3.88) higher risk of NTM-PD. In the subgroup analysis stratified by seropositivity, seropositive patients with RA had a 3.77-fold (95% CI 3.00 to 4.73) higher risk of NTM-PD than controls, whereas participants with seronegative RA did not have a significantly higher risk (adjusted HR 1.18, 95% CI 0.68 to 2.04). Stratified analyses showed a more prominent association of RA with NTM-PD in males, alcohol drinkers and obese individuals (p<0.05).
conclusionThe risk of incident NTM-PD was approximately threefold higher in participants with RA than in matched controls, although the association was significant only for patients with seropositive RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.